Aberrant activation of m6A demethylase FTO renders HIF2αlow/- clear cell renal cell carcinoma sensitive to BRD9 inhibitors.
ChuanJie ZhangLu ChenWeiJuan LouJunHui SuJingYi HuangAo LiuYang XuHongChao HeYi GaoDanFeng XuQingQuan LiPublished in: Science translational medicine (2021)
[Figure: see text].
Keyphrases